Statute Details
- Title: Human Biomedical Research Act 2015 (HBRA2015)
- Full Title: An Act to regulate the conduct of human biomedical research, further regulate certain restricted human biomedical research, prohibit certain types of human biomedical research, regulate tissue banks and tissue banking activities, prohibit commercial trading of human tissue, and provide for matters connected therewith.
- Type: Act of Parliament
- Current status (per extract): Current version as at 26 Mar 2026
- Legislative structure (high level): 10 Parts (Preliminary; Administration; Consent; Institutional Review Boards; Regulation of Research; Regulation of Tissue Banks; Codes of Practice and Ethics; Enforcement; Appeals; Miscellaneous)
- Key subject areas: Consent; institutional review; prohibited/restricted research; tissue banking; anti-commercial trading; enforcement powers
- Key provisions (from extract): ss 3, 6–14, 15–21, 22–31, 32–39, 40–41, 42–53, 54–55, 56–65; Schedules 1–5
- Related legislation (from metadata): Healthcare Services Act 2020; Inquiries Act 2007
What Is This Legislation About?
The Human Biomedical Research Act 2015 (“HBRA”) is Singapore’s core statute governing how human biomedical research is conducted and how human tissue is handled for research purposes. In plain terms, it sets legal rules to protect research participants (including vulnerable groups), ensure ethical oversight, and regulate the use and storage of human biological material through tissue banks.
The Act also draws a sharp line between research that is permitted (subject to safeguards), “restricted” research that requires additional controls, and “prohibited” research that is not allowed at all. This tiered approach reflects the reality that some biomedical research poses greater risks to individuals, to privacy and confidentiality, or to public trust—particularly where tissue is involved or where identification risks are higher.
Finally, the HBRA regulates tissue banking activities and prohibits commercial trading of human tissue. This is designed to prevent exploitation, reduce incentives that could undermine consent, and ensure that tissue is handled for legitimate research and clinical purposes under regulated governance.
What Are the Key Provisions?
Definitions and scope (ss 2–3; Schedules 1–2). The Act’s starting point is its definitions. Section 3 clarifies what counts as “human biomedical research” and what is meant by “supervision and control”. The scope is further refined by Schedules: the First Schedule excludes certain “human biological material” from the definition of “human tissue”, and the Second Schedule excludes certain “research, studies and matters” from the definition of “human biomedical research”. For practitioners, these schedules are critical: they determine whether a project is regulated by the HBRA or falls outside it.
Consent requirements (Part 3; ss 6–14). The HBRA places consent at the centre of lawful research. Section 6 requires “appropriate consent” to be taken before research involving human subjects proceeds. The Act then addresses consent in complex scenarios: adults who lack mental capacity (s 7), minors (s 8), and tissue removal or use for research where the subject is an adult lacking capacity (s 9) or a minor (s 10). There is also a specific regime for research involving deceased persons (s 11).
Procedural safeguards are built in. Section 12 requires information to be provided before consent is taken—ensuring that consent is informed rather than merely formal. Section 13 allows an institutional review board (IRB) to waive certain requirements for appropriate consent in defined circumstances, while Section 14 permits withdrawal of consent. For lawyers advising sponsors or institutions, the practical takeaway is that consent documentation, information sheets, and withdrawal processes must be aligned with the HBRA’s requirements, not merely with general ethics committee practice.
Institutional Review Boards (Part 4; ss 15–21). The HBRA requires IRBs to be appointed and notified (s 15) and provides for appointment by multiple research institutions (s 16). IRBs have defined functions and duties (s 17), including reviewing research proposals and ensuring compliance with consent and other safeguards.
Operationally, the Act regulates IRB composition, quorum, and proceedings (s 18), and requires management of conflicts of interest (s 19). Section 20 provides for an application to the IRB for review, and Section 21 provides an appeal against an IRB decision. This matters because IRB decisions can determine whether a project may proceed, whether consent requirements may be waived, and whether conditions are imposed. Practitioners should ensure that IRB processes are properly documented to support compliance and to withstand scrutiny during enforcement or appeals.
Conduct of research and institutional duties (Part 5; ss 22–29). Section 22 imposes duties on researchers regarding the conduct of human biomedical research and their obligations to comply with the Act. Section 23 sets out functions and duties of research institutions, and Section 24 requires a “declaration of compliance” by the research institution. These provisions create institutional accountability: compliance is not only an individual researcher matter.
Section 25 reiterates the need for appropriate consent from research subjects. Section 26 addresses the issue of “compelling” a person to participate in research—prohibiting coercion and reinforcing voluntariness. Sections 27–29 focus on information and biological material protections: researchers and institutions must protect health information and human biological material against loss and unauthorised disclosure, and there are restrictions on disclosure of information (s 29). Importantly, Section 28 prohibits re-identification of anonymised information or biological material without consent. This is a privacy and confidentiality safeguard with direct implications for data governance, coding practices, and any future linkage studies.
Prohibited and restricted research (ss 30–31; Schedules 3–4). The Act distinguishes between prohibited and restricted human biomedical research. Section 30 prohibits certain types of research, while Section 31 regulates “restricted” research. The detailed lists are in Third Schedule (prohibited research) and Fourth Schedule (restricted research). For legal practice, these schedules are often the decisive factor in risk assessment: even if consent is obtained, a project may still be unlawful if it falls within prohibited categories.
Regulation of tissue banks and tissue banking activities (Part 6; ss 32–39). Part 6 regulates tissue banks and tissue banking activities. Section 32 prohibits commercial trading of human tissue, and Section 33 prohibits advertisements relating to such commercial trading. This is a strong anti-market rule aimed at preventing commodification of human tissue.
Section 34 requires notification of a tissue bank, and Section 35 sets out duties of a tissue bank. Section 36 requires a declaration of compliance by the tissue bank. Section 37 restricts activities relating to human tissue, while Section 38 addresses “compelling” a person to donate tissue—again reinforcing voluntariness and prohibiting coercion. Section 39 restricts disclosure of information on tissue donors, aligning with confidentiality principles and donor privacy.
Codes of practice and ethics (Part 7; ss 40–41). The HBRA contemplates codes of practice or ethics. Section 40 allows for such codes, and Section 41 provides for their use. In practice, these codes can operationalise compliance by translating statutory duties into practical standards—such as consent processes, governance structures, and data handling expectations. Lawyers should treat codes as interpretive and compliance tools, particularly where the Act uses broad concepts like “appropriate consent” and “protection” of information.
How Is This Legislation Structured?
The HBRA is organised into ten Parts. Part 1 contains preliminary provisions, including definitions that determine whether an activity is regulated. Part 2 establishes administration mechanisms, including advisory committees. Part 3 sets out consent rules across different categories of participants and tissue use scenarios, including waiver and withdrawal. Part 4 creates the IRB framework, including composition, duties, review processes, and appeals.
Part 5 regulates the conduct of human biomedical research, including researcher and institutional duties, consent, privacy protections, and the key prohibitions/restrictions. Part 6 regulates tissue banks and tissue banking activities, including anti-commercial trading rules and donor protections. Part 7 addresses codes of practice and ethics. Part 8 provides enforcement powers, including immediate stoppage and inspection/search powers. Part 9 provides appeals mechanisms. Part 10 contains miscellaneous provisions such as exemptions, service of documents, court jurisdiction, and transitional/saving provisions.
Who Does This Legislation Apply To?
The HBRA applies to persons and institutions involved in human biomedical research and tissue banking activities in Singapore, including researchers, research institutions, and tissue banks. It also applies to IRBs and their decision-making processes, because IRB review and declarations of compliance are central to lawful research.
In terms of subject matter, the Act applies to research that falls within the statutory definition of “human biomedical research” and to “human tissue” as defined (with exclusions in the First Schedule). It also applies differently depending on whether the research is classified as prohibited or restricted under the Third and Fourth Schedules. Accordingly, applicability is both person-based (who conducts/oversees) and activity-based (what is being done).
Why Is This Legislation Important?
The HBRA is important because it gives legal force to ethical and participant-protection principles in biomedical research. Consent is not treated as a mere ethical preference; it is a statutory requirement with detailed rules for vulnerable groups (minors and adults lacking mental capacity) and for tissue use. Privacy and confidentiality are also explicitly protected, including restrictions on re-identification of anonymised material.
From an enforcement perspective, the Act is designed to be effective. Part 8 includes powers for immediate stoppage of research or tissue banking activity (s 42), orders prohibiting persons from conducting research or tissue banking (s 43), and robust inspection/search powers (s 45). It also includes provisions on disposal of articles/documents (s 46), confidentiality protections for informers (s 47), and “protected information” (s 49). For practitioners, these powers mean that compliance failures can trigger rapid regulatory intervention, not only post-hoc penalties.
The Act also addresses corporate liability and organisational responsibility. Enhanced penalties for corporations (s 50), liability of employers for acts of employees (s 51), and offences by bodies corporate (s 52) underscore that institutions cannot avoid responsibility by pointing to individual misconduct. In addition, the Act provides for appeals (Part 9), including appeal to the Minister and an Appeals Advisory Panel, which supports procedural fairness while maintaining regulatory control.
Related Legislation
- Healthcare Services Act 2020
- Inquiries Act 2007 (referred to for ministerial appointment of a committee of inquiry)
Source Documents
This article provides an overview of the Human Biomedical Research Act 2015 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.